PD-1 VS PD-L1 Inhibitors in Metastatic Cancers
DOI:
https://doi.org/10.47611/jsrhs.v11i4.3695Keywords:
Immunotherapy, Metastatic Cancer, PD-1, PD-L1Abstract
Immunotherapy is a new and developing field with the potential to change the way medical professionals approach diseases with high mortality rates such as metastatic cancers. However, due to the little time immunotherapy has been around, there has been little testing to evaluate the effectiveness of immunotherapeutic devices in metastatic cancers. This study in particular will compare the efficacy of immunotherapeutic devices that block PD-1 inhibitors and PD-L1 inhibitors based on research available on the subject. The goal of this study is to see which immunotherapeutic drug group has the most potential as a treatment for metastatic cancers as of now and to introduce more awareness to this sort of treatment in the oncological field.
Downloads
References or Bibliography
Alva, A., Mangat, P., Garrett-Mayer, E., Halabi, S., Hansra, D., Calfa, C., . . . Schilsky, R. (2021, August 01).
Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: Results from
the targeted agent and Profiling Utilization Registry (Tapur) study. Retrieved May 2, 2022, from
https://www.ingentaconnect.com/content/wk/jco/2021/00000039/00000022/art00005
André, T., Grothey, A., Simões, E., & Offit, P. (2020, December 03). Pembrolizumab in microsatellite-
instability–high advanced colorectal cancer: Nejm. Retrieved May 2, 2022, from
https://www.nejm.org/doi/full/10.1056/NEJMoa2017699
Antonarakis, E. S., Piulats, J. M., & Gross-Goupile, M. (2019). Pembrolizumab for Treatment-Refractory Metastatic
Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Retrieved
May 2, 2022, from https://ascopubs.org/doi/10.1200/JCO.19.01638
ASCO. (2022, February 14). Colorectal Cancer - Statistics. Retrieved May 2, 2022, from
https://www.cancer.net/cancer-types/colorectal-cancer/statistics
Astor, L. (2019, May 3). Atezolizumab Combo Falls Short In Phase III CRC Trial. Retrieved May 2, 2022, from
https://www.targetedonc.com/view/atezolizumab-combo-falls-short-in-phase-iii-crc-trial
Barroso-Sousa, R., Keenan, T., Li, T., Tayob, N., Trippa, L., Pastorello, R., . . . Tolaney, S. (2021, August 25).
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: A phase ii and
Biomarker Study. Retrieved May 2, 2022, from https://www.nature.com/articles/s41523-021-00287-9
Cancer Research Institute. (2022). Cancer immunotherapy timeline of progress. Retrieved May 2, 2022, from
https://www.cancerresearch.org/en-us/immunotherapy/timeline-of-progress
Dirix, L., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H., Forero-Torres, A., . . . Hamilton, E. (2018,
February). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast
cancer: A phase 1b javelin solid tumor study. Retrieved May 2, 2022, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807460/
Han, Y., Liu, D., & Li, L. (2020, March 1). PD-1/PD-L1 pathway: Current researches in cancer. Retrieved May 2,
, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136921/
Hoffman, M. (2022, March 01). Prostate cancer survival rates: What they mean. Retrieved May 2, 2022, from
https://www.webmd.com/prostate-cancer/prostate-cancer-survival-rates-what-they-
mean#:~:text=Once%20prostate%20cancer%20has%20spread,for%20five%20years%20after%20diagnosis
.
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2001, January 01). The extrinsic and intrinsic roles of PD-
L1 and its receptor PD-1: Implications for immunotherapy treatment. Retrieved May 2, 2022, from
https://www.frontiersin.org/articles/10.3389/fimmu.2020.568931/full
Kim, H., Gurrin, L., Ademi, Z., & Liew, D. (2014, January). Overview of methods for comparing the efficacies of
drugs in the absence of head-to-head clinical trial data. Retrieved May 2, 2022, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895352/#:~:text=Na%C3%AFve%20direct%20comparis
on%20between%20two,comparators%20between%2Famong%20the%20trials.
Kim, J. H., Kim, S. Y., Baek, J. Y., & Cha, Y. J. (2020, August 24). A Phase II Study of Avelumab Monotherapy in
Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or Pole-Mutated Metastatic or
Unresectable Colorectal Cancer. Retrieved May 2, 2022, from https://pubmed.ncbi.nlm.nih.gov/32340084/
Kuznar, W. (2020, December 20). High Responses Observed with Avelumab Added to Regimen for Metastatic
Colorectal Cancer Does Not Translate to PFS. Retrieved May 2, 2022, from
https://www.onclive.com/view/high-responses-observed-with-avelumab-added-to-regimen-for-metastatic-
colorectal-cancer-does-not-translate-to-pfs
Kwan, E., Spain, L., & Anton, A. (2021, September 04). Avelumab Combined with Stereotactic Ablative Body
Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Retrieved May 2, 2022, from https://www.europeanurology.com/article/S0302-2838(21)01979-5/fulltext
Lenz, H., Cutsem, E. V., Limon, M. L., & Wong, K. (2020, May 29). First-Line Nivolumab Plus Low-Dose
Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer:
The Phase II CheckMate 142 Study. Retrieved May 2, 2022, from
https://ascopubs.org/doi/abs/10.1200/JCO.21.01015
Mapes, D. (2016, October 13). Living with stage 4: The Breast Cancer No One Understands. Retrieved May 2,
, from https://www.fredhutch.org/en/news/center-news/2014/10/stage-4-metastatic-misunderstood-
breast-
cancer.html#:~:text=Between%2020%20and%2030%20percent,the%20disease%20takes%2040%2C000%
lives.
Miles, D., Gligorov, J., Andre, F., Barata, T., & O'Shaughnessy, J. (2021, January 01). Primary results from
IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or
without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Retrieved
May 2, 2022, from https://www.annalsofoncology.org/article/S0923-7534(21)02026-3/fulltext
National Cancer Institute. (2022, April 07). Immune checkpoint inhibitors. Retrieved May 2, 2022, from
https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors
Rodriguez-Bigas, M., Lin, E. H., & Crane, C. H. (2003). Stage IV Colorectal Cancer. Retrieved May 2, 2022, from
https://www.ncbi.nlm.nih.gov/books/NBK13267/
Southall, J. (2021, December 10). Nivolumab Plus Ipilimumab Shows Benefit In Metastatic HER2-Negative Breast
Cancer. Retrieved May 2, 2022, from https://www.healio.com/news/hematology-
oncology/20211210/nivolumab-plus-ipilimumab-shows-benefit-in-metastatic-her2negative-breast-
cancer#:~:text=Nivolumab%20plus%20ipilimumab%20induced%20durable,San%20Antonio%20Breast%2
Cancer%20Symposium.
Stenger, M. (2021, August 20). Cetuximab Plus Avelumab as Rechallenge Therapy for RAS Wild-type Metastatic
Colorectal Cancer. Retrieved May 2, 2022, from https://ascopost.com/news/august-2021/cetuximab-plus-
avelumab-as-rechallenge-therapy-for-ras-wild-type-metastatic-colorectal-
cancer/#:~:text=The%20investigators%20concluded%2C%20%E2%80%9CThe%20findings,of%20patient
s%20who%20could%20benefit.%E2%80%9D
Sweeney, C., Gillessen, S., Rathkopf, D., & Matsabura, N. (2014). IMbassador250: A Phase III Trial Comparing
Atezolizumab With Enzalutamide vs Enzalutamide Alone in Patients With Metastatic Castration-Resistant
Prostate Cancer. Retrieved May 02, 2022, from https://www.annalsofoncology.org/article/S0923-
(19)52228-1/fulltext#relatedArticle
The University of Texas. (n.d.). Immune checkpoint inhibitors. Retrieved May 2, 2022, from
https://www.mdanderson.org/treatment-options/immune-checkpoint-inhibitors.html
Published
How to Cite
Issue
Section
Copyright (c) 2022 Saswat Saravanan
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
